, 50% and 70% (ACR20, ACR50 and ACR70)
reduction of symptoms with ACTEMRA plus DMARD therapies compared to the
control group. In the TOWARD trial, ACR20, ACR50 and ACR70 was achieved in
61%, 38% and 21%, respectively, of ACTEMRA plus DMARDs patients versus 25%,
9% and 3%, respectively, in the placebo plus DMARDs arm. In the OPTION
trial, 59%, 44% and 22%, respectively, of patients treated with ACTEMRA
(8mg/kg) plus methotrexate achieved ACR20, ACR50 and ACR70 compared with
27%, 11% and 2%, respectively, in the placebo plus methotrexate control
arm.
"We are excited to announce these results as they indicate that ACTEMRA
and its unique IL-6 inhibition may become a significant new treatment
option for people suffering from RA," said Lars Birgerson, M.D., Ph.D, Vice
President, Global Head Medical Affairs, Roche. "Findings from these studies
will be part of the application to the U.S. Food and Drug Administration
that we intend to submit by year's end."
In the TOWARD trial, disease remission was demonstrated in 30% of
ACTEMRA patients (DAS28 <2.6) compared with 3.4% of patients treated with
only DMARDs. In the OPTION trial disease remission was demonstrated in 28%
of ACTEMRA patients (DAS28 <2.6) compared with 1% of patients treated with
methotrexate alone. In both studies, levels of C-reactive protein (CRP), a
marker of inflammation, and hemoglobin levels, showed an improvement within
two weeks and remained at normal levels through the end of both studies.
According to both studies, patients treated with ACTEMRA plus
anti-rheumatic therapies experienced greater improvements in quality of
life and function measures, including fatigue, physical and mental
functions compared to placebo plus anti-rheumatic treatments.
Other Studies
The TOWARD and OPTION trials are part of a large clinical development
program that enrolled more than 4,000 RA patients in 41 countries,
including the United States and several European countries. Two others,
RADIATE (Rese
'/>"/>
SOURCE Roche Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related medicine technology :1.
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain2.
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML3.
Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet4.
Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint5.
Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate6.
CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation7.
Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule8.
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma9.
Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)10.
Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma11.
Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial